Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL

Michael Northend, William Wilson, Wendy Osborne, Christopher P. Fox, Andrew Davies, Dima El‐Sharkawi, Elizabeth H. Phillips, Hau Wui Sim, Shalal Sadullah, Nimish Shah,

Blood Advances · 2022 · 44 citations · 14 references

DOIFull text

Open access

Concepts

Abstract

For Pola-BR, the objective response rate (ORR) was 62.5% (complete response [CR] rate was 50%). Median progression-free survival (PFS) a at 9.2 months and overall survival (OS) at 12.4 months were both superior for Pola-BR. 9 A single-arm expansion cohort identified primary refractory

References

14